Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 1/20 | 0.63 |
| ▸ | BTK | Q06187 | 7/20 | 0.54 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.51 |
| ▸ | GRM5 | P41594 | 7/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | TEC | P42680 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31379801 | 1.00 | TNK2 (0.63) | TNK2BTKGRM1GRM5EGFR | |
| SCHEMBL16597782 | 1.00 | TNK2 (0.63) | TNK2BTKGRM1GRM5EGFR | |
| SCHEMBL16597764 | 0.91 | TNK2 (0.54) | TNK2BTKGRM1GRM5EGFR | |
| SCHEMBL31386570 | 0.91 | TNK2 (0.54) | TNK2BTKGRM1GRM5EGFR | |
| SCHEMBL16598127 | 0.90 | GRM1 (0.51) | TNK2BTKGRM1GRM5PDE10A | |
| SCHEMBL31386584 | 0.90 | GRM1 (0.51) | TNK2BTKGRM1GRM5PDE10A | |
| SCHEMBL16671349 | 0.89 | TNK2 (0.54) | TNK2BTKGRM1GRM5PDE10A | |
| SCHEMBL16598041 | 0.88 | BTK (0.55) | TNK2BTKEGFRTEC | |
| SCHEMBL31386629 | 0.86 | TNK2 (0.61) | TNK2BTKGRM1GRM5PDE10A | |
| SCHEMBL16597807 | 0.86 | TNK2 (0.61) | TNK2BTKGRM1GRM5PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2025-02-20 | — | — | US | disclosed |
| US-12202813-B2 | Process for preparing 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide | BEIJING INNOCARE PHARMA TECH CO., LTD (CN) | 2025-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | TNK2 59/4885BTK 1/4885GRM1 2375/4885 |
| US-12202813-B2 | Process for preparing 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide | NAMPT, NNT, NAPRT | TNK2 829/4885BTK 3716/4885GRM1 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.